SYNCOMF · NSE
Syncom Formulations (India) Limited
₹20.04
+6.71% (+₹1.26)
Prev. close
₹18.78
Volume
1,02,60,532
Delivery %
31.8%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Syncom Formulations (India) Limited
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, creams, liquids orals, and effervescent. Further, it provides liquid vials and ampoule injections, dry vial injections and inhalers; manufacturing and trading of nutraceuticals, dietary supplements, health supplements, functional foods, herbal and ayurvedic preparations, vitamins, minerals, proteins, antioxidants, natural extracts, organic and wellness products, and all related healthcare and nutrition-based goods and real estate business. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Ankit Kedarmal Bankda
Headquarters
Indore
Employees
902
Website
syncomformulations.comExchange
View on NSE ↗Key stats
Market cap
₹1,883.76 Cr
P/E ratio (TTM)
22.3
Dividend yield
0.50%
EPS (TTM)
₹0.90
Beta (1Y · daily vs NIFTY 50)
1.53
Beta (5Y · monthly vs NIFTY 50)
1.97
Shares float
46.98 Cr
EPS · quarter ended Jun 2026
₹0.26
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 1.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹244.81 Cr | ₹219.66 Cr | ₹224.25 Cr | ₹263.39 Cr | ₹457.37 Cr | ₹489.17 Cr | |
| EBITDA | ₹44.98 Cr | ₹31.46 Cr | ₹34.24 Cr | ₹43.15 Cr | ₹71.42 Cr | ₹108.29 Cr |
| ₹29.17 Cr | ₹19.79 Cr | ₹20.07 Cr | ₹25.31 Cr | ₹49.43 Cr | ₹76.44 Cr | |
| Diluted EPS | — | — | ₹0.22 | ₹0.27 | ₹0.53 | ₹0.81 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹291.65 Cr | ₹308.24 Cr | ₹377.83 Cr | ₹404.66 Cr | ₹413.28 Cr | ₹533.85 Cr | |
| ₹62.09 Cr | ₹57.79 Cr | ₹83.18 Cr | ₹72.49 Cr | ₹4.58 Cr | ₹1.49 Cr | |
| Stockholders' equity | ₹187.58 Cr | ₹222.22 Cr | ₹256.01 Cr | ₹288.14 Cr | ₹342.16 Cr | ₹414.99 Cr |
Current assets, Non-current assets, Fixed assets, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹10.53 Cr | ₹-5.96 Cr | ₹23.44 Cr | ₹58.08 Cr | |
| Investing cash flow | — | — | ₹-44.95 Cr | ₹83.02 Cr | ₹-18.20 Cr | ₹-50.62 Cr |
| — | — | ₹35.00 Cr | ₹-14.56 Cr | ₹-67.90 Cr | ₹-3.02 Cr | |
| Capital expenditure | — | — | ₹-20.63 Cr | ₹-8.14 Cr | ₹-9.96 Cr | ₹-11.67 Cr |
| End cash position | — | — | ₹87.97 L | ₹63.38 Cr | ₹71.20 L | ₹5.15 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Nov 22–Jun 26(16Q) |
|---|---|
| Promoter | 50.57% |
| Public | 49.43% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Syncom Formulations (India) Limited | ₹1,763.44 Cr | ₹19.46 | 20.8 | 4.25 | 18.4% | 0.00 | +5.3% | +9.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 28
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.